BRITISH MEDICAL JOURNAL 1 SEPTEMBER 1979 521 presence, that confers risk. It is extremely difficult to compare groups of patients because of the wide variation between individual patients, but there was nothing in our results to suggest that arrhythmias that occur often and yet do not cause haemodynamic problems are any more dangerous than those that occur only occasionally. Although our patients were taking sufficient doses of propranolol and atenolol to reduce their maximum and mean heart rates, we found little evidence that these drugs had any useful antiarrhythmic action. Beta-blockers have antiarrhythmic properties when administered acutely, and in higher doses than we used they might have a prophylactic effect. A relatively high proportion of our patients, however, suffered sufficient hypotension to necessitate withdrawal from treatment, and we do not believe that in suspected acute myocardial infarction it is practicable routinely to give more than 40 mg propranolol thrice daily or 50 mg atenolol twice daily.
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Even if beta-blockers have little antiarrhythmic effect in suspected myocardial infarction they may still reduce mortality by some other means. Beta-blockers are known, for example, to influence platelet behaviour18 and may limit infarct size.1'
Our findings raise grave doubts about the value of studying arrhythmias to assess drugs intended to reduce mortality from myocardial infarction. Only clinical trials with death as an endpoint show the value of a drug; once a drug has been found to be effective then studies such as the one we have described may be needed to elucidate its mode of action. 
Results
There were no significant differences in serum 25-OHD concentrations between patients receiving long-term anticonvulsant treatment and healthy controls (fig 1) . But concentration of radioassayable 24,25(OH)2D and the mean 24, 25(OH)2D:25-OHD ratios were significantly (P<0-01) lower in patients receiving phenobarbitone (3-25 155 nmol/l (1-30±0-62 ng/ml) and 0-067 ±0023 respectively) and in patients receiving phenytoin (3-00 1-22 nmol/l (1-20±0-49 ng/ml) and 0-057±0-026) than in the controls (5-42±2-32 nmol/l (2-17±0.98 ng/ml) and 0-100±0-033) (figs 2 and 3).
Serum 24,25(OH)2D concentrations were under 1-75 nmol/1 (0-7 ng/ml) and the 24,25(OH)2D:25-OHD ratio less than 0-05 in four patients with radiological evidence of osteopenia.
Serum calcium concentrations were significantly (P<0-05) lower in the patients than in the controls, while serum inorganic phosphate concentrations were significantly lower in the phenytoin group than in either the controls or the patients taking phenobarbitone (see table) . Thus in patients in institutions and in northern populations in whom serum 25-OHD values are low the changes in 25-OHD metabolism may produce very low or undetectable concentrations of 24,25(OH)2D. On the other hand, the administration of vitamin D, which increases serum substrate (25-OHD) concentration, might enhance 24,25(OH) 2D synthesis and subsequently its serum concentrations despite the effect of the anticonvulsants.
